Genome editing among bioethics and regulatory practices

In the last decade genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the debate about the bioethics and the regulatory practices of genome editing is still far from satis-factory answers. This delay results from an excessive emphasis on the effectiveness of the genome editing technologies that is relevant for the regulatory practices, but not at a bioethical level. In-deed, other factors (such as accessibility and acceptability) could make these techniques not ac-cepted at the bioethical level also in the presence of their 100% effectiveness.